Mindy Kile, PA
Medical · Arkansas City, KSNPI 1346573078
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2021 at $1,550 and has fallen 88.2% since, to $184 in 2025.
Across 237 payments — averaging $13.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$764
- Novo Nordisk$363
- Amgen$344
- Lilly USA, LLC$187
- Amarin Pharma, Inc.$159
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$153
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,151100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $764 |
| Novo Nordisk | 35 | $363 |
| Amgen(2 entities) | 24 | $344 |
| Lilly USA, LLC | 17 | $187 |
| Amarin Pharma, Inc. | 13 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $153 |
| Agile Therapeutics, Inc. | 6 | $118 |
| Sanofi-aventis U.S. LLC | 9 | $116 |
| Astellas Pharma US Inc | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $79 |
| Eisai Inc. | 6 | $78 |
| Exeltis, USA Inc. | 5 | $75 |
| Bayer | 4 | $73 |
| Mayne Pharma Commercial LLC | 4 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Hologic Sales And Service, LLC | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 2 | $28 |
| Si-bone, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Johnson & Johnson | 2 | $24 |
| Pfizer | 1 | $24 |
| Biogen | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Coopersurgical, Inc. | 1 | $17 |
| Stryker | 1 | $17 |
| Myriad Women's Health, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Abbott | 1 | $15 |
| Apria Healthcare LLC | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Neos Therapeutics, LP | 1 | $11 |
| AstraZeneca | 1 | $11 |
How this compares
$3,151 in reported general payments places this provider in the 75th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $561 |
Paid to pharmacies, not to this prescriber.
Other medical in Arkansas City
- Linly StevensOverland Park$111K
- Shana ArnholdShawnee$82K
- Richard AllenbachWichita$70K
- Laura LudlowTopeka$61K
- Anita KishOlathe$58K
- Kathryn WelchWichita$32K
- Courtney SteneOverland Park$22K
- Janella DewittOverland Park$19K
- Walter DeanMission$16K
- Jason MengesWichita$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.